Wealthiest 10% Drive Climate Change, Study Reveals

A US F-18 Super Hornet fighter jet was lost in the Red Sea on May 6, marking the second such incident involving the Harry S Truman aircraft carrier within a week. According to unnamed US officials cited by Reuters, the jet failed to stop properly after landing on the carrier, resulting in it tipping off the flight deck. Both crew members successfully ejected before the jet plunged into the sea and were later rescued by a helicopter. CNN reported that the jet has not been recovered and that last week's incident also involved a fighter jet falling overboard during evasive maneuvers against Houthi fire. On the day of this most recent crash, the Iran-backed Houthi rebel group reportedly fired at the Truman, hours after former President Donald Trump announced a ceasefire. This escalation comes as the Truman continues to support US strikes against Houthi forces in Yemen.

In a controversial statement, Stephen Miller, deputy chief of staff for policy in the Trump administration, revealed that the White House is "actively looking at" the possibility of suspending habeas corpus. This right allows individuals to challenge the legality of their detention. Miller's remarks follow President Donald Trump's consideration of extreme measures to tackle illegal immigration in the United States. Miller indicated that the Constitution permits suspension of this privilege during times of invasion, suggesting that the administration's response would depend on how federal courts rule on immigration-related issues. "If judges fail to make Team Trump happy," he stated, alternative measures might be explored. Legal experts, including MSNBC correspondent Lisa Rubin and Georgetown University law professor Steve Vladeck, criticized Miller's approach as unconstitutional. They emphasized that the Suspension Clause applies only in cases of rebellion or invasion and cannot be unilaterally imposed by the President, especially while Congress is in session. The conversation has ignited concerns about the direction of U.S. immigration policy and the implications for civil liberties.

A groundbreaking immunotherapy, termed immunoablative therapy, has shown remarkable success, with 84 out of 100 participants experiencing complete cancer remission. This treatment focuses on patients with a specific genetic mutation, called mismatch repair deficiency, which enhances their response to the therapy using a humanized mouse antibody known as dostarlimab. According to the research published in the New England Journal of Medicine, 80% of participants, who had cancer types such as esophageal, stomach, colon, liver, bladder, uterus, and prostate cancers, saw their tumors vanish. Patients like 71-year-old Maureen Sideris, who was diagnosed with gastroesophageal cancer, report feeling rejuvenated post-treatment. Sideris remarked, “The cancer has disappeared in my PET images and biopsies,” while oncologist Luis Alberto Díaz emphasized the therapy’s potential to spare patients from more aggressive treatments like chemotherapy and surgery. The therapy costs approximately $55,000 per patient, but Díaz notes it can ultimately reduce overall healthcare costs. Researchers stress that long-term benefits are still being evaluated, particularly for non-rectal cancer cases.